Skip to main content
logo
Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
38.06
-0.43 (-1.12%)
Jul 31, 2026, 4:00 PM EDT - Market closed

Celldex Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.871.557.026.882.364.65
Revenue Growth
-88.54%-77.99%1.99%192.02%-49.32%-37.30%
Gross Profit
0.871.557.026.882.364.65
Operating Income
-309.06-287.37-195.08-154.54-115.23-71.24
Net Income
-283.65-258.76-157.86-141.43-112.33-70.51
Earnings Per Share
-4.26-3.90-2.45-2.92-2.40-1.64
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
451.46518.57725.28423.6304.95408.25
Total Debt
3.143.574.766.535.024.6
Net Cash (Debt)
448.32515.01720.53417.07299.93403.65
Net Cash Growth
-33.07%-28.52%72.76%39.06%-25.70%115.20%
Net Cash Per Share
6.757.7511.198.616.409.42

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-222.16-210.95-157.78-107.29-103.73-60.91
Capital Expenditures
-4.09-2.71-1.92-1.82-1.83-1.25
Free Cash Flow
-226.25-213.66-159.7-109.11-105.56-62.16
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-35688.50%-18599.80%-2778.89%-2245.27%-4889.01%-1531.78%
Pretax Margin
-32753.58%-16748.03%-2248.76%-2054.76%-4765.59%-1520.92%
Profit Margin
-32753.60%-16748.00%-2248.76%-2054.76%-4765.59%-1516.04%
FCF Margin
-26125.80%-13829.10%-2274.89%-1585.20%-4478.57%-1336.44%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3453.651169.89238.93322.00892.55388.23